Michael P Stansky bought $1.5M of TriSalus Life Sciences (TLSI)
Executed Feb 23, disclosed Feb 23, the same day.
Over the 21 trading sessions from the disclosed entry session (Feb 23), the stock returned -28.3% (delay-adjusted); from the execution session (Feb 23), -28.3%. Derived: entry at the session's open, exit at the close 20 sessions later.
Michael P Stansky (Director) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in TriSalus Life Sciences, Inc. (TLSI). Across 2 priced purchase filings, the average 21-session return was +20.5% from execution and +13.7% from disclosure (delay-adjusted; derived). The largest single filing was $1.5M of TLSI (610,000 sh across 2 lots, as filed), executed May 15.
Healthcare · TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-on…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→610,000 sh across 2 lots
Exec May 15
Filed May 18 · 4:42 PM ET